Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma
CTR20140501Phase 3Completed
- Sponsor
- Biotech Pharmaceutical
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biotech Pharmaceutical. Started Nov 2015; status: completed.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20140501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140501.